“Response Genetics continues to make great strides as a company. During this past year, we successfully launched our ResponseDX: Lung and ResponseDX: Colon genetic tests; brought the promise
The new drug application (NDA) of T-614 was submitted to the Japanese Ministry of Health, Labour and Welfare by the companies on September 24, 2003. Subsequent interviews with
According to Digirad, the Cardius X-Act is a rapid cardiac Single photon emission computed tomography (SPECT)/VCT imaging system that features a low-dose volume-computed tomography (VCT) attenuation correction system
Results of Operations Year ended December 31, 2008 compared to year ended December 31, 2007 Cost of Revenues and Gross Profit Cost of revenue for 2008, was $2,879,839
DKSH will provide Cardima with an integrated solution, including regulatory, logistics, marketing, sales, physician training, distribution and after-sales services. Cardima’s electrophysiology products and surgical ablation system have received
Under the terms of the agreement Alnara will obtain exclusive worldwide rights to develop and market liprotamase. Robert Beall, president and CEO of the Cystic Fibrosis Foundation Therapeutics
The agreement resolves litigation that was pending in the US District Court of Texas with respect to certain CR Bard products. The technology generally relates to surgical devices
The company expects to begin Phase III clinical trials at multiple sites across the US in the second quarter of 2009. As part of this investigational new drug
Deni Zodda, the company’s chief business officer, has been appointed interim CFO and corporate secretary. The company has also hired Joseph Warusz as a consultant, who will serve
Boehringer Ingelheim has reported that the last patient has completed treatment in the Phase III randomized evaluation of long term anticoagulant therapy study. This randomized evaluation of long
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.